Skip to content
Open access

Unveiling the antitumor and chemo-sensitizing effects of ondansetron in the treatment of MCF-7 breast cancer cells

Nov 2026 · Scientific Reports · Vol 16 · 0 citations · 61 references

Abstract

Breast cancer (BC) remains one of the global leading causes of cancer-related deaths among women. Resistance to chemotherapy and metastatic progression are key challenges. Serotonin (5-HT) and its receptor subtypes are implicated in tumor proliferation, but the oncogenic role of 5-HT3-Rs in BC is not well defined. The widely-used antiemetic, Ondansetron, is a selective 5-HT3 receptor antagonist, that is investigated in this study to explore the potential previously-unrecognized anticancer properties in MCF-7 human BC cells. To investigate the potential effect of Ondansetron, alone or in combination with Doxorubicin, in inhibiting proliferation, survival and migration of MCF-7 BC cells, and to explore some of the underlying molecular mechanisms. MCF-7 cells were treated with Ondansetron and/or Doxorubicin. Cell viability- (MTT), migration- (wound healing), and survival- (clonogenic) assays were conducted. The regulation of some downstream signaling pathways were analyzed by ELISA, Western blotting, or immunofluorescence to assess the modulations of migratory/metastatic (RAS/mTOR/SRC/FAK/MMP-2), survival/angiogenic (Cyclin D1/VEGF-A), and apoptotic (Bcl-2/Cytochrome c/cleaved-caspase-7) biomarkers. Ondansetron significantly reduced cell viability and migration capability and markedly potentiated the cytotoxic effects of Doxorubicin. The combination regimen, downregulated key oncogenic signaling molecules (RAS/mTOR/SRC/FAK/MMP-2/VEGF-A/Cyclin D1) with enhanced Cytochrome c/cleaved-caspase-7 activation, and suppressed the anti-apoptotic protein, Bcl-2. Pharmacological targeting of 5-HT/HTR3 with Ondansetron induces antitumor effects in MCF-7 BC cells by suppressing 5-HT3-mediated survival signaling and metastatic pathways, and increases MCF-7 cells sensitivity to chemotherapy. This study proposes using Ondansetron as a potential adjuvant to Doxorubicin-based treatment of BC, to improve efficacy and reduce toxicity of the chemotherapy.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.